COSTA MESA, CA--(Marketwire - November 07, 2008) - CNS Response, Inc. (OTCBB: CNSO) reported today the results of a study presented at the U.S. Psychiatric and Mental Health Congress by Charles DeBattista, D.M.H., M.D., Professor of Psychiatry and Behavioral Sciences, Director of Depression and Psychopharmacology Clinics, Stanford University School of Medicine, Palo Alto, Calif. The poster presentation, titled "Referenced-EEG Guidance of Medications for Treatment-Resistant Depressed Patients - A Pilot Study," provided an analysis of medical outcomes of treatment-resistant depressed patients, when medicated based on a standard treatment approach, the TMAP depression algorithm (Texas Medication Algorithm Project), compared with patients medicated based on rEEG®-guided medication choices. The full poster presentation and analysis of results are available at www.cnsresponse.com/trdposterpresentation.
